ARRY-371797: Phase II started

Array began an open-label, U.S. Phase II trial to evaluate 2 dose levels of oral ARRY-797 for 48 weeks in about 12 patients with symptomatic DCM due to an LMNA gene mutation. ARRY-797 has also complet...